KBI Biopharma, a Durham, North Carolina-headquartered biopharmaceutical contract development and manufacturing organization, has acquired the manufacturing and laboratory assets of Opexa Therapeutics, a biotechnology company based in The Woodlands, Texas, which includes the lease of a 10,200-square-foot cGMP manufacturing facility in The Woodlands, Texas.

With the acquisition, KBI gains facilities for the development and manufacture of clinical-stage cellular therapy products, including three ISO7 cGMP manufacturing suites,flow cytometry and analytical infrastructure, and logistics and warehousing operations. Under Opexa management, the facility manufactured autologous cell therapy products for five clinical trials, including two Phase IIb trials.

KBI has named Donald Healey, PhD, formerly the chief scientific officer of Opexa Therapeutics, as senior vice president of operations and site head for the facility.

Source: KBI Biopharma